Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revervia is a premium, plant-based nutraceutical ingredient developed by Aker BioMarine, consisting of docosahexaenoic acid (DHA) derived from the microalgae *Schizochytrium sp.* It is produced through a sustainable, solvent-free fermentation process and contains 40-60% DHA in its natural triglyceride form. Marketed as a vegan-friendly alternative to fish oil, Revervia is intended for oral administration as a dietary supplement to support brain health, eye health, and prenatal/pregnancy health. It is primarily sold as a bulk oil to B2B customers for formulation into finished consumer health products, providing a clean-label and sustainable source of essential omega-3 fatty acids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Revervia.